1. Home
  2. ABLV vs FGEN Comparison

ABLV vs FGEN Comparison

Compare ABLV & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.74

Market Cap

39.5M

Sector

N/A

ML Signal

HOLD

Logo FibroGen Inc

FGEN

FibroGen Inc

HOLD

Current Price

$8.63

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
FGEN
Founded
2015
1993
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
35.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ABLV
FGEN
Price
$0.74
$8.63
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$146.50
AVG Volume (30 Days)
1.1M
40.8K
Earning Date
01-13-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
53.38
Revenue
$114,319,869.00
$8,298,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.28
$0.16
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$4.85
52 Week High
$1.77
$21.94

Technical Indicators

Market Signals
Indicator
ABLV
FGEN
Relative Strength Index (RSI) 39.81 47.05
Support Level $0.74 $8.36
Resistance Level $0.75 $9.19
Average True Range (ATR) 0.06 0.64
MACD -0.02 0.06
Stochastic Oscillator 12.75 16.59

Price Performance

Historical Comparison
ABLV
FGEN

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Share on Social Networks: